DUAC Drug Patent Profile

When do Duac patents expire, and when can generic versions of Duac launch?

Duac is a drug marketed by Stiefel and is included in one NDA.

The generic ingredient in DUAC is benzoyl peroxide; clindamycin phosphate. There are seventeen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the benzoyl peroxide; clindamycin phosphate profile page.

Summary for DUAC

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	53
Drug Prices:	Drug price information for DUAC
DailyMed Link:	DUAC at DailyMed

See drug prices for DUAC

Paragraph IV (Patent) Challenges for DUAC

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DUAC	Gel	benzoyl peroxide; clindamycin phosphate	1% / 5%	050741	1	2008-12-11

US Patents and Regulatory Information for DUAC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Stiefel	DUAC	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050741-001	Aug 26, 2002	AB	RX	Yes	No

Expired US Patents for DUAC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Stiefel	DUAC	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050741-001	Aug 26, 2002	5,466,446

International Patents for DUAC

See the table below for patents covering DUAC around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2142530	COMPOSITIONS TOPIQUES CONTENANT DU PEROXYDE DE BENZOYLE ET DE LA CLINDAMYCINE, ET METHODE D'UTILISATION (TOPICAL COMPOSITIONS CONTAINING BENZOYL PEROXIDE AND CLINDAMYCIN AND METHOD OF USE THEREOF)

Supplementary Protection Certificates for DUAC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0137963	97C0042	Belgium		PRODUCT NAME: 2-(2-BENZOYL-SUBSTITUE)-1,3-CYCLOHEXANE-DIONES; REGISTRATION NO/DATE: 8452/B 19930121
1586316	122011100019	Germany		PRODUCT NAME: BROMFENAC (2-AMINO-3-(4-BROMOBENZOYL)PHENYLESSIGSAEURE); REGISTRATION NO/DATE: EU/1/11/692/001 20110518
1458369	CA 2008 00029	Denmark		PRODUCT NAME: ADAPALEN, BENZOYLPEROXID
0526708	C300097	Netherlands		PRODUCT NAME: BOSENTAN, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN HYDRAAT OF IN DE VORM VAN EEN ESTER VAN DE HYDROXYLGROEP VAN DE 2-HYDROXYETHOXY REST MET EEN ZUUR MET DE FORMULE R5-OH, WAARIN R5 EEN C1-7-ALKANOYL, BENZOYL, OF HETEROCYCLYCARBONYL VOORSTELT; NATL. REGISTRATION NO/DATE: U/1/02/220/001 - 005 20020515; FIRST REGISTRATION: CH IKS 58841 01 - 02 20020228
1458369	C01458369/01	Switzerland		PRODUCT NAME: ADAPALENUM + BENZOYLIS PEROXIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 58460 19.05.2009
1667986	92172	Luxembourg		PRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)

Last updated: April 25, 2026

DUAC: Market Dynamics and Financial Trajectory

What is DUAC and where does it sit in the dermatology market?

DUAC is a topical prescription dermatology product in the acne category. It is marketed as a combination gel containing clindamycin and benzoyl peroxide, aimed at mild to moderate acne. In the US, the DUAC brand footprint is shaped by two forces that dominate prescription acne markets: (1) off-patent generics and (2) prescriber and payer preference for combination topical regimens. In practice, the DUAC franchise’s financial trajectory has been governed less by clinical differentiation over time and more by generic competition, rebate intensity, and formulary access.

How does DUAC’s competitive landscape drive price and volume?

Topical acne is one of the most structurally competitive segments in dermatology because multiple active ingredients and combination strategies exist and because pharmacy benefit managers (PBMs) often steer utilization to lower-cost options. For branded DUAC, the primary dynamics are:

• Generic erosion of clindamycin/benzoyl peroxide combinations (or therapeutically equivalent regimens) that compress net pricing.
• Channel share transfer to lower-cost branded or generic combinations through formulary tiering.
• Manufacturer rebate pressure to maintain access in covered lives.

Market structure effect: Acne topical therapy is heavily influenced by plan design and pharmacy cost controls. DUAC’s ability to sustain revenue depends on whether it can win formulary position against generic equivalents and competing branded acne products.

What do DUAC’s commercialization signals imply about its financial trajectory?

From a patent and competitive standpoint, DUAC behaves like a mature branded topical product: as generic competitors enter and PBMs tighten formulary status, net sales usually follow a pattern of:

1. Early peak while branded exclusivity and preferred formulary access exist
2. Gradual volume loss as patients and prescribers shift to lower-cost alternatives
3. Net price compression as rebates intensify and list price increases do not fully protect revenue
4. Ongoing sales decline after broad generic adoption reaches pharmacies and wholesalers

For decision-making in R&D and licensing, the key takeaway is that DUAC’s trajectory is not primarily driven by new clinical evidence. It is driven by access and reimbursement economics.

How do payers and formulary mechanics typically impact DUAC?

Payer behavior in acne dermatology generally follows consistent rules that affect DUAC-like brands:

• Formulary tiering: branded products face meaningful copay differentials versus generics, pushing adherence and persistence issues.
• Prior authorization and step edits: even when not widely applied, utilization controls can shift to alternatives after initial attempts.
• Rebate and contracting strategy: branded revenue often hinges on contracting outcomes with PBMs and large payers, not on wholesale acquisition cost.

Net result for DUAC: As lower-cost alternatives become available, the brand must either (a) defend a higher rebate-backed net price or (b) accept loss of covered share.

Where are the main revenue levers for DUAC?

For mature topical acne brands, the financial trajectory is usually determined by a small set of operational levers:

• Covered lives and formulary access (managed by contracting and rebate level)
• Script volume and persistence (influenced by patient out-of-pocket cost)
• Trade and channel inventory management (wholesaler ordering behavior around pricing moves and generic entry)
• Product line breadth (strength of SKU mix across concentrations and patient-use patterns)

DUAC’s combination mechanism (antibiotic plus oxidizing agent) supports clinical utility in acne regimens, but it does not immunize revenue from the reimbursement math that favors lower-cost alternatives.

---

Financial Trajectory Framework (What to Expect Over Time)

How does DUAC revenue typically behave after generic entry?

Once generic equivalents capture meaningful formulary share, a branded topical product’s financial behavior usually becomes:

• Net sales decline driven by both reduced prescriptions and lower net price.
• Margin compression if the brand increases rebates to regain coverage.
• Shift in marketing spend efficiency toward formulary wins and high-propensity prescriber segments.

This pattern fits the business reality of topical dermatology: clinical differentiation exists but payer economics decide utilization at scale.

What is the likely path for DUAC’s unit economics?

In mature branded topical segments:

• List price can rise without saving revenue if net price is forced down through rebates.
• Gross-to-net erosion increases when PBMs demand higher concessions to maintain preferred status.
• Sales stabilization sometimes occurs when the brand retains a residual share among prescribers who prefer the specific regimen, but continued generic pressure typically prevents durable recovery.

Implication for investors and partners: The value proposition shifts from “growth” to “defense,” and deal terms (license value, exclusivity scope in any reformulation, distribution terms) should reflect a defensible share rather than a growth curve.

---

DUAC and Corporate/Deal Relevance

What does DUAC’s market profile mean for licensing or BD decisions?

For partners evaluating derm brands or topical acne pipelines, DUAC is best treated as an asset class benchmark for:

• Formulation and lifecycle management (new vehicle, concentration, or delivery form can sometimes extend commercial utility if it creates payer differentiation or if the change is patent-protected)
• Contracting strategy discipline (PBM coverage is the dominant determinant once exclusivity expires)
• Rational expectations for revenue trajectory (a mature topical franchise typically declines unless protected by strong differentiation or remaining exclusivity)

What R&D signals align with DUAC’s market economics?

In areas where DUAC-type products face generic competition, R&D that matters commercially tends to include:

• Reformulation that creates patentable protection and clinically meaningful tolerability
• Fixed-dose combinations that maintain efficacy while improving adherence
• Dermatology regimen development that aligns with payer step edits and guideline-driven workflows

Where those elements do not exist, the brand behaves like a declining asset.

---

Key Takeaways

• DUAC’s commercial trajectory in acne dermatology is dominated by generic competition, formulary tiering, and rebate intensity, not by a new wave of clinical differentiation.
• The typical pattern for mature branded topical acne products is volume loss plus net price compression, leading to persistent net sales decline.
• In payer-driven segments like acne, contracting and access to covered lives become the core revenue levers.
• For investment or BD, DUAC functions as a benchmark for defense economics rather than growth economics after generic adoption.

---

FAQs

1) What drives DUAC’s revenue more than clinical differentiation?

Formulary access, PBM contracting, rebates, and the availability of lower-cost therapeutic alternatives.

2) Why do topical acne brands typically face sharper revenue pressure than some other dermatology categories?

Because acne topical therapy has multiple interchangeable options and payer cost controls steer utilization to generics and preferred low-cost regimens.

3) Does DUAC’s combination approach prevent market share erosion?

It supports clinical use, but it does not prevent erosion when payer economics favor generic equivalents or alternative combinations.

4) What are the most important metrics to track for DUAC’s financial outlook?

Net sales trend, net price (gross-to-net), covered lives/formulary status, and prescription script volume.

5) What would a “re-acceleration” scenario require for DUAC?

Sustained formulary wins that withstand generic pressure or meaningful lifecycle extensions (patent-protected reformulation or delivery changes) that translate into payer differentiation.

---

References

[1] FDA. (n.d.). DUAC (clindamycin phosphate and benzoyl peroxide) topical gel product information and labeling. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/